organization · Reporting owner
WFD Ventures Fund II, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | 10% owner | March 08, 2017 | March 09, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectWFD Ventures Fund II, L.P. | 43,000 |
Reported balance
After 2017-03-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-03-08 · Other · Disposed 19,732,767 · Balance 43,000 F1: On March 8, 2017, WFD Ventures Fund II, L.P. distributed, on a pro-rata basis and without consideration, to its economic partners 19,732,767 of the Issuer's shares, including 625,954 of such shares to WFD-GP II, LLC. F2: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 84,699 |
Reported balance
Holding disclosure · report date 2017-03-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 84,699 |
| Ordinary SharesSEC Table I · non-derivative | IndirectWFD-GP II, LLC | 625,954 |
Reported balance
Holding disclosure · report date 2017-03-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 625,954 F1: On March 8, 2017, WFD Ventures Fund II, L.P. distributed, on a pro-rata basis and without consideration, to its economic partners 19,732,767 of the Issuer's shares, including 625,954 of such shares to WFD-GP II, LLC. F2: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 8, 2017, WFD Ventures Fund II, L.P. distributed, on a pro-rata basis and without consideration, to its economic partners 19,732,767 of the Issuer's shares, including 625,954 of such shares to WFD-GP II, LLC.
F2: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2017 Filed Mar 9, 2017 22:08 UTC | NovoCure Ltd NVCR · Entity 4494 | OtherOrdinary Shares | 19,732,767 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-007012 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund II, L.P. Disclosed balance after: 43,000 F1 · kind: On March 8, 2017, WFD Ventures Fund II, L.P. distributed, on a pro-rata basis and without consideration, to its economic partners 19,732,767 of the Issuer's shares, including 625,954 of such shares to WFD-GP II, LLC. F1 · price: On March 8, 2017, WFD Ventures Fund II, L.P. distributed, on a pro-rata basis and without consideration, to its economic partners 19,732,767 of the Issuer's shares, including 625,954 of such shares to WFD-GP II, LLC. F2 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionWarrants · Derivative | 525,618 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0000899243-17-006165 · doc4.xml · derivative · entry 7 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund II, L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 525,618 shares Expires 2018-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Currently exercisable as of the date hereof. F1 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionWarrants · Derivative | 686,836 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0000899243-17-006165 · doc4.xml · derivative · entry 6 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund II, L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 686,836 shares Expires 2017-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Currently exercisable as of the date hereof. F1 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 248,285 | $7.60 | $1,886,966.00 |
DisclosureSEC source: 0000899243-17-006165 · doc4.xml · nonDerivative · entry 4 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund II, L.P. Disclosed balance after: 19,775,767 F3 · kind: Reflects 248,285 ordinary shares withheld by the issuer at the market price of $7.60 per share less an exercise price of $3.59 per share in connection with the cashless exercise of 277,333 warrants to purchase ordinary shares owned by WFD Ventures Fund II, L.P. F1 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 525,618 | $3.59 | $1,886,968.62 |
DisclosureSEC source: 0000899243-17-006165 · doc4.xml · nonDerivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund II, L.P. Disclosed balance after: 20,024,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 324,440 | $7.60 | $2,465,744.00 |
DisclosureSEC source: 0000899243-17-006165 · doc4.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund II, L.P. Disclosed balance after: 19,498,434 F2 · kind: Reflects 324,440 ordinary shares withheld by the issuer at the market price of $7.60 per share less an exercise price of $3.59 per share in connection with the cashless exercise of 362,396 warrants to purchase ordinary shares owned by WFD Ventures Fund II, L.P. F1 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 686,836 | $3.59 | $2,465,741.24 |
DisclosureSEC source: 0000899243-17-006165 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund II, L.P. Disclosed balance after: 19,822,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: The Amendment filed on Form 4/A on February 21, 2017 incorrectly reflected the total number of ordinary shares beneficially owned by WFD Ventures Fund II, L.P. WFD Ventures Fund II, L.P. beneficially owned 19,136,038 ordinary shares following the transactions reported by the aforementioned Form 4/A. F1 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:01 UTC | NovoCure Ltd NVCR · Entity 4494 | OtherOrdinary Shares | 2,242,664 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-000224 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman · 10% owner WFD Ventures Fund II, L.P. · CIK 0001481972 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · WFD Ventures Fund A, LLC Disclosed balance after: 0 F1 · kind: On January 3, 2017, WFD Ventures Fund A, LLC distributed to its sole economic member all of the Issuer shares that it held in connection with its liquidation. Neither Mr. Doyle nor WFD Ventures Fund II, L.P. had any pecuniary interest in the distributed shares. F1 · price: On January 3, 2017, WFD Ventures Fund A, LLC distributed to its sole economic member all of the Issuer shares that it held in connection with its liquidation. Neither Mr. Doyle nor WFD Ventures Fund II, L.P. had any pecuniary interest in the distributed shares. F2 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, which is the managing member of WFD Ventures Fund A, LLC. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.